T. Rowe Price Associates
SRTA

T. Rowe Price Associates’s Strata Critical Medical Inc SRTA Stock Holding History

T. Rowe Price Associates’s Portfolio SRTA Stock Details SRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$286K Buy
54,196
+1,828
+3% +$9.62K ﹤0.01% 2867
2026
Q1 		$219K Buy
52,368
+11,086
+27% +$53.4K ﹤0.01% 2809
2025
Q4 		$199K Buy
41,282
+7,198
+21% +$34.8K ﹤0.01% 2812
2025
Q3 		$173K Buy
34,084
+3,934
+13% +$17.4K ﹤0.01% 2823
2025
Q2 		$122K Buy
30,150
+5,342
+22% +$17.4K ﹤0.01% 2856
2025
Q1 		$68K Buy
24,808
+1,955
+9% +$7.01K ﹤0.01% 2888
2024
Q4 		$98K Buy
22,853
+2,565
+13% +$9.77K ﹤0.01% 2833
2024
Q3 		$60K Buy
20,288
+911
+5% +$2.9K ﹤0.01% 2906
2024
Q2 		$68K Buy
19,377
+3,556
+22% +$11.9K ﹤0.01% 2810
2024
Q1 		$46K Buy
15,821
+566
+4% +$1.75K ﹤0.01% 2881
2023
Q4 		$54K Buy
15,255
+2,408
+19% +$6.91K ﹤0.01% 2801
2023
Q3 		$34K Buy
12,847
+1,280
+11% +$4.5K ﹤0.01% 2818
2023
Q2 		$46K Buy
11,567
+676
+6% +$2.15K ﹤0.01% 2812
2023
Q1 		$37K Buy
+10,891
New +$44.4K ﹤0.01% 2819

Other funds holding SRTA

TP
Third Point New York $4.68B AUM 37.3% 1-Year Est. Return
NRCM
Northern Right Capital Management Darien, Connecticut $337M AUM 63.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
PLC
Pillsbury Lake Capital San Francisco, California $366M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's SRTA Position: Q2 2026 in Review

T. Rowe Price Associates increased its Strata Critical Medical Inc (SRTA) stake by 3.5% in Q2 2026, buying an estimated $9.62K and bringing the position to 54,196 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #2867.

T. Rowe Price Associates first reported a position in SRTA in Q1 2023 and has held it in 14 quarters since. 139 funds tracked by Wall St. Rank hold SRTA as of Q2 2026.

  • T. Rowe Price Associates held 54,196 shares of Strata Critical Medical Inc worth $286K as of Q2 2026.
  • T. Rowe Price Associates bought 1,828 Strata Critical Medical Inc shares in Q2 2026, an estimated $9.62K.
  • Strata Critical Medical Inc made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2867 holding.
  • T. Rowe Price Associates first reported a position in Strata Critical Medical Inc in Q1 2023 and has held it in 14 quarters since.
  • 139 funds tracked by Wall St. Rank held Strata Critical Medical Inc as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.